Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
N4 Pharma ( (GB:N4P) ) has provided an update.
N4 Pharma has announced positive results from its first in vivo study of the N4 101 programme, an orally delivered anti-inflammatory treatment for Inflammatory Bowel Disease (IBD) using its Nuvec® technology. The study demonstrated significant reductions in inflammation and a marked increase in efficacy when targeting specific cells, showcasing the potential of Nuvec® as a leading nucleic acid delivery technology. These findings are expected to strengthen N4 Pharma’s position in the biotech industry and enhance discussions with commercial partners as they advance the programme into further development stages.
More about N4 Pharma
N4 Pharma is a pre-clinical biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is working on building a preclinical data set and aims to achieve first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
Average Trading Volume: 1,744,751
Technical Sentiment Signal: Sell
Current Market Cap: £8M
For an in-depth examination of N4P stock, go to TipRanks’ Stock Analysis page.